SCARLET (Supplemental Citicoline Administration to Reduce Lung injury Efficacy Trial): study protocol for a single-site, double-blinded, placebo-controlled, and randomized Phase 1/2 trial of i.v. citicoline (CDP-choline) in hospitalized SARS CoV-2-infected patients with hypoxemic acute respiratory failure
Sonal Pannu(Oklahoma City University), Elliott D. Crouser(The Ohio State University), Guy Brock(The Ohio State University), Joshua A. Englert(The Ohio State University Wexner Medical Center), Matthew C. Exline(The Ohio State University), Qing Wu(Changsha Central Hospital), Philip Diaz(The Ohio State University), Joseph S. Bednash(The Ohio State University Wexner Medical Center), Amy Bartlett(The Ohio State University), Ian C. Davis(The Ohio State University)
Cited by 1
Related Papers
Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome
|Nature Immunology|2010|3k
Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2020|1k
The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.
|PubMed|2014|504
Circadian rhythm reprogramming during lung inflammation
|Nature Communications|2014|270
Mitochondria in lung biology and pathology: more than just a powerhouse
|American Journal of Physiology-Lung Cellular and Molecular Physiology|2014|198